Yumi Matsumura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yumi Matsumura has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Yoshiki Miyachi
4 shared publicationsMayumi Katoh
Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2 shared publicationsSatoshi Kore‐Eda
Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2 shared publicationsAkiko Arakawa
1 shared publicationAyako Kojima
Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
1 shared publicationChisa Nakashima
Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
1 shared publication
Latest Publications
- Open Access
- 1 November 2020
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 12, 207-215
Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database
Purpose: Eculizumab, a drug that blocks activation of the terminal complement pathway, is useful in the treatment of several rare diseases. However, eculizumab-related meningococcal disease is a serious problem. Because of the difficulty diagnosing meningococcal disease, deaths from meningococcal disease may have been overlooked. The purpose of this study was to clarify the trend of meningococcal infection in patients on eculizumab and to evaluate the effectiveness of risk communication. Methods: Pharmacovigilance analysis was conducted using the Japanese Adverse Drug Event Report database between the first quarter of 2010 and the second quarter of 2019. Of the reports of deaths, those with adverse event terms of fever, shock, altered state of consciousness, loss of consciousness, sepsis, organ failure, and disseminated intravascular coagulation were analyzed as deaths with suspected meningococcal infection. Results: Of the 3559.2 person-years of eculizumab-exposed patients, 17 patients died with symptoms of meningococcal disease (including two confirmed cases). The mortality rate of meningococcal disease in patients exposed to eculizumab in Japan was estimated to be 0.56 (confirmed cases) to 4.8 (suspected cases) per 1000 person-years. Based on data from the National Epidemiological Surveillance of Infectious Disease, the mortality rate of meningococcal disease in the general population in Japan is 0.0042 per 100,000 person-years. Thus, the mortality rate from meningococcal disease in eculizumab-exposed patients is estimated to be 13,000 to 114,000 times the mortality rate from meningococcal disease in the general population of Japan. Academic societies warned of deaths from meningococcal disease in the first quarter of 2018, calling for appropriate action. Thereafter, only one death with symptoms of meningococcal disease has been reported. Conclusion: The analysis of the database showed that death from meningococcal disease in eculizumab-exposed individuals may occur more often than expected. This study also showed that appropriate risk communication reduced the fatality rate of meningococcal disease.
- 1 November 2020
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 12, 207-215
Open AccessRisk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database
Purpose: Eculizumab, a drug that blocks activation of the terminal complement pathway, is useful in the treatment of several rare diseases. However, eculizumab-related meningococcal disease is a serious problem. Because of the difficulty diagnosing meningococcal disease, deaths from meningococcal disease may have been overlooked. The purpose of this study was to clarify the trend of meningococcal infection in patients on eculizumab and to evaluate the effectiveness of risk communication. Methods: Pharmacovigilance analysis was conducted using the Japanese Adverse Drug Event Report database between the first quarter of 2010 and the second quarter of 2019. Of the reports of deaths, those with adverse event terms of fever, shock, altered state of consciousness, loss of consciousness, sepsis, organ failure, and disseminated intravascular coagulation were analyzed as deaths with suspected meningococcal infection. Results: Of the 3559.2 person-years of eculizumab-exposed patients, 17 patients died with symptoms of meningococcal disease (including two confirmed cases). The mortality rate of meningococcal disease in patients exposed to eculizumab in Japan was estimated to be 0.56 (confirmed cases) to 4.8 (suspected cases) per 1000 person-years. Based on data from the National Epidemiological Surveillance of Infectious Disease, the mortality rate of meningococcal disease in the general population in Japan is 0.0042 per 100,000 person-years. Thus, the mortality rate from meningococcal disease in eculizumab-exposed patients is estimated to be 13,000 to 114,000 times the mortality rate from meningococcal disease in the general population of Japan. Academic societies warned of deaths from meningococcal disease in the first quarter of 2018, calling for appropriate action. Thereafter, only one death with symptoms of meningococcal disease has been reported. Conclusion: The analysis of the database showed that death from meningococcal disease in eculizumab-exposed individuals may occur more often than expected. This study also showed that appropriate risk communication reduced the fatality rate of meningococcal disease.
- 1 September 2012
- Published by JLE in European Journal Of Dermatology
- Vol. 22 (5) , 658-662
Atypical clinical appearance of eosinophilic pustular folliculitis of seborrheic areas of the face
Eosinophilic pustular folliculitis is a pruritic eruption that preferentially involves the face. It is characterized by well-demarcated erythema, extending peripherally with a central clearing and pigmentation, together with sterile pustules lining the periphery. We describe five cases of eosinophilic pustular folliculitis with pruritic papules and erythema on seborrheic areas of the face, which lacked the typical features of classic eosinophilic pustular folliculitis--pustules and peripheral extension--but showed eosinophilic infiltration of the hair follicles, histologically. The eruption quickly responded to oral indomethacin except for one case that responded to tranilast and one case that was associated with acquired immunodeficiency syndrome, with recurrences in defined areas of the face. Our findings in these cases suggest that eosinophilic pustular folliculitis may vary in clinical appearance.
- 1 September 2012
- Published by JLE in European Journal Of Dermatology
- Vol. 22 (5) , 658-662
Atypical clinical appearance of eosinophilic pustular folliculitis of seborrheic areas of the face
Eosinophilic pustular folliculitis is a pruritic eruption that preferentially involves the face. It is characterized by well-demarcated erythema, extending peripherally with a central clearing and pigmentation, together with sterile pustules lining the periphery. We describe five cases of eosinophilic pustular folliculitis with pruritic papules and erythema on seborrheic areas of the face, which lacked the typical features of classic eosinophilic pustular folliculitis--pustules and peripheral extension--but showed eosinophilic infiltration of the hair follicles, histologically. The eruption quickly responded to oral indomethacin except for one case that responded to tranilast and one case that was associated with acquired immunodeficiency syndrome, with recurrences in defined areas of the face. Our findings in these cases suggest that eosinophilic pustular folliculitis may vary in clinical appearance.
- 19 May 2011
- Published by Wiley in The Journal of Dermatology
- Vol. 38 (10) , 1037-1040
Pellagra‐like erythema on sun‐exposed skin of patients with anorexia nervosa
- 19 May 2011
- Published by Wiley in The Journal of Dermatology
- Vol. 38 (10) , 1037-1040
Pellagra‐like erythema on sun‐exposed skin of patients with anorexia nervosa
- 21 March 2011
- Published by Wiley in The Journal of Dermatology
- Vol. 38 (11) , 1102-1105
Pyoderma gangrenosum in a patient with myelodysplastic syndrome followed by possible extracutaneous manifestations in the gallbladder, liver, bone and lung
- 21 March 2011
- Published by Wiley in The Journal of Dermatology
- Vol. 38 (11) , 1102-1105
Pyoderma gangrenosum in a patient with myelodysplastic syndrome followed by possible extracutaneous manifestations in the gallbladder, liver, bone and lung